Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
Predictiemodel biedt handvat voor follow-up van barrettslokdarm
sep 2022 | Endoscopie, Maag-darm-leveroncologie